Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Cycadopsida”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

345 records · Page 20Linked to original sources

Cycad palm toxicosis in dogs: 60 cases (1987-1997).

OBJECTIVE: To report clinical and epidemiologic information, summarize characteristic clinical signs and laboratory results, and describe the expected course of cycad toxicosis in dogs. DESIGN: Retrospective study. ANIMALS: 60 dogs with evidence of cycad ingestion. PROCEDURE: The National Animal Poison Control Center's case record database was searched for records of dogs ingesting cycad plants from January 1987 to November 1997. Data were retrieved on clinical signs, laboratory test results, exposure history, and physical examination findings. Cases were assessed as toxicosis, suspected toxicosis, or possible toxicosis. RESULTS: Records from 60 dogs were retrieved; 89.7% of the dogs were from the southern United States, 38.7% ingested seeds, 95% developed liver and gastrointestinal tract problems, and 53.3% had abnormal neurologic signs. High serum bilirubin concentration and alkaline phosphatase and alanine aminotransferase activities were the most common serum biochemical abnormalities. Although clinical signs were observed within 1 day, laboratory values did not change for 24 to 48 hours after cycad ingestion. Mortality rate was reportedly 32.1%. CLINICAL IMPLICATIONS: 68% of dogs responded well to treatment and supportive care. Dogs ingesting seeds are likely to develop more serious problems. Clinical signs can develop within 1 to 3 days and can last for several days. A tentative diagnosis should be made on the basis of history of ingestion, clinical signs, and duration of signs. Because of the nature of these toxins, cycad ingestion is serious and should be treated aggressively.

Animals↗

[Therapeutic effect of shuxuening combining neuroleptics for the treatment of chronic schizophrenia--a double blind study].

OBJECTIVE: To assess the therapeutic effect of Shuxuening (SXN), the extractum of Ginkgo biloba761 (EGb761) in treating chronic schizophrenia. METHODS: A double-blind, placebo-controlled multi-center research on the treatment of chronic schizophrenics with SXN was used. Five hundred and forty-five patients were randomly divided into either SXN group or the control group. Patients in the former group received SXN 120 mg three times daily. Patients in both groups received their maintenance neuroleptics throughout the 16-week research treatment. RESULTS: The patients' rating scores of brief psychiatric rating scale (BPRS) and Scale for the Assessment of Negative Symptoms reduced much greater in SXN group than those in the control group from the sixth week of treatment (P < 0.01). The effect of SXN for BPRS factors of retardation and thought disturbance was better than that of the control. SXN presented a better therapeutic effect for chronic schizophrenics than the control when rated with traditional global rating method as well, in which 44.98% marked improvement was obtained in SXN group compared to 20.98% in the control group. CONCLUSION: SXN combining neuroleptics, was an effective medicine for chronic schizophrenics. Moreover, it appeared few side-effects within the recommended dose range.

Adult↗

[Effects of ginkgo leave concentrated oral liquor in treating asthma].

OBJECTIVE: To determine the effects of Ginkgo leave concentrated oral liquor (GLC) on airway inflammation. METHODS: Airway hyperreactivity and clinical symptoms and pulmonary functions of asthma patients were determined. RESULTS: In contrast to placebo group, GLC significantly reduced airway hyperreactivity (P < 0.05) and improved clinical symptoms (P < 0.05), pulmonary functions (P < 0.05) of the asthmatic patients. CONCLUSION: GLC is an effective drug of anti airway inflammation.

Adolescent↗